Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 217: Japanese Investment in North Carolina’s Life Sciences Industry with David Robinson of Maynard Nexsen
Legal Alert | Japan is Primed for Increased Foreign Direct Investment
Patent Grace Period Considerations in Australia, Japan, South East Asia and the U.S.
Greater Speed and Efficiency: Steps IP Offices Around the World Are Taking to Streamline the Patent Process
Nota Bene Episode 109: Asia Q1 Check In: China’s Emergence as the Number One World Economy and New Hegemonic Role in Asia with Paul Kim
Nota Bene Episode 69: Asia Check In: The Coronavirus’s Impact on Business, the Trilateral Summit, and Japan’s Criminal Justice System with Paul Kim
Dr. Frederick Ch’en discusses generic drugs and the changing pharmaceutical landscape in Asia
Spencer Klein Talks M&A with Mergers & Acquisitions Magazine
On June 9, 2025, biosimilar manufacturers Samsung Bioepis and Alvotech announced separate deals to expand their respective offerings in Japan and Europe. ...more
Wilson Sonsini is pleased to present the latest edition of The Life Sciences Report. This issue features an article on managing IP development and capture at growing medtech start-ups that offers insight from executives at...more
The Japan Fair Trade Commission ("JFTC") periodically conducts market research to review and investigate business activities that may violate abuse of superior bargaining position ("ASBP") regulations. For the first time in...more
Law360 recently published an article by David Kappos , former director of the U.S. Patent and Trademark Office, describing and analyzing the Japan Patent Office’s final draft of its "Guide to Licensing Negotiations Involving...more
Aging populations and rising healthcare costs across Asia — particularly in Japan — have created new market opportunities for generic drug makers operating in the region. For originator drug manufacturers, that means...more
On January 21, 2016, the Japan Fair Trade Commission (“JFTC”) published revisions to its guidelines for the Antimonopoly Act (“AMA”). The new guidelines make it a fair trade practice violation for holders of a standard...more